Adamax for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Adamax for Health & Longevity

Created on 10/02/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Adamax, a lab-made peptide sold online as a longer-acting version of the Russian nasal peptide medicine Semax, is sought for sharper thinking and long-term brain protection. No human or animal study of Adamax itself has been published, and its chemical structure differs between suppliers. Its benefits are borrowed from small Semax studies and rest at low or speculative confidence, and products may be impure or not the labeled molecule. (Full Review)

Protocol

Community-reported Adamax dosing
100–500 µg per day
Intranasal or subcutaneous injection, courses of 10–30 days; no validated protocol, figures from vendors and user communities, not trials
Semax-derived intranasal approach
Sub-milligram daily (0.1% solution)
For cognitive indications; 6–18 mg per day (1% solution) in stroke trials
Time of day
Morning or early afternoon
User reports link evening doses with delayed sleep onset
Time to effect
Peptic Ulcer Healing
By day 14
Intranasal Semax added to standard ulcer medication
Neuroprotection in Stroke and Chronic Cerebrovascular Disease
1–3 weeks
Semax stroke-recovery effects; no Adamax time course has been measured
Mood, Motivation and Quality of Life
Peak on day 10
Of a 12 mg per day intranasal Semax course

Benefits

Contraindications
  • Pregnant or breastfeeding women
  • People under 18 years
  • Active psychosis, mania, bipolar I disorder or severe anxiety disorders
  • History of seizures or epilepsy
  • Active cancer or cancer treated within the past 5 years
  • Bleeding disorders, a platelet count below 100 ×10⁹/L, or an INR above the therapeutic target
  • Known hypersensitivity to Semax or related peptides
    •
Key Interactions
  • Stimulants (amphetamine, lisdexamfetamine, methylphenidate): Caution
  • Serotonergic antidepressants (sertraline, fluvoxamine) and MAO inhibitors (phenelzine): Caution
  • Adamantane drugs (memantine, amantadine): Caution
  • Other nootropic peptides (Selank, N-acetyl Semax amidate): Caution
  • Surgery and anesthesia: Caution
  • Antipsychotics (haloperidol, risperidone): Monitor
  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel): Monitor
  • Opioids (morphine, oxycodone): Monitor
  • Decongestant nasal sprays (oxymetazoline, xylometazoline): Monitor
  • Caffeine and pseudoephedrine: Monitor
  • NSAIDs (ibuprofen, naproxen, aspirin): Monitor
  • Neurotrophic supplements (lion's mane): Monitor
  • Dopaminergic supplements (L-tyrosine, Mucuna pruriens): Monitor
  • Serotonergic supplements (5-HTP, St. John's wort): Monitor
  • Antiplatelet supplements (fish oil, Ginkgo biloba, high-dose vitamin E): Monitor
    •

Risk & Side Effects

  • High:
  • Medium:
  • Low: Nasal Irritation, Headache and Injection-Site Reactions; Seizure-Like Brain Activity
    •
  • Speculative: Uncertain Product Identity, Purity and Sterility; Overstimulation, Anxiety and Sleep Disruption; Adamantane-Related Nervous-System Effects; Bleeding Tendency; Growth-Signal Stimulation; Immune Reactions to a Novel Peptide
    •

Monitoring

Marker Target Why
Platelet count 200–300 ×10⁹/L Bleeding-risk baseline
Prothrombin time / INR INR 0.9–1.1 (not anticoagulated) Clotting reference
ALT Below 25 U/L Liver screen for a novel compound
eGFR Above 90 mL/min/1.73 m² Kidney clearance of peptides
Morning cortisol 10–18 µg/dL Confirms absence of hormonal effect
Serum BDNF No established target; track change from own baseline Target pathway
Blood pressure Below 120/80 mmHg Stimulant-type effect
Resting heart rate 50–70 bpm Overstimulation signal
Cognitive test battery (reaction time, digit span) Before vs. after each course Personal efficacy signal

Cadence: Baseline before a first course; blood pressure, heart rate, sleep and mood at 1 week; complete blood count and comprehensive metabolic panel at the end of each 10–14-day course, then every 3–6 months while courses continue; INR checks added for anyone on anticoagulants (within 1 week of starting).

Qualitative Assessment

  • Focus and mental clarity during demanding work
  • Verbal fluency and word recall
  • Mood and motivation
  • Sleep onset and sleep quality
  • Anxiety or restlessness
  • Nasal comfort and absence of nosebleeds
  • Headache frequency
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.